Advertisement

Stimulation of adenosine receptors on myeloid cells enhances leukocyte migration at the site of burn injury

  • K. S. Yuryeva
  • K. V. Nevskaya
  • A. N. Dzuman
  • O. P. Ikkert
  • V. V. Ivanov
  • I. V. Saltikova
  • A. E. Sazonov
  • L. M. Ogorodova
Article
  • 25 Downloads

Abstract

Adenosine, endogenous purine nucleoside, is an ATP metabolite that also acts as an extracellular signaling molecule. The concentration of extracellular adenosine rises during hypoxia and cell damage leading to numerous pleiotropic effects. Although it has been shown that local adenosine concentrations are significantly increased during burn injury their effects at the site of the damage remain poorly investigated. Circulating myeloid cells express surface specific adenosine receptors and during burn injury they migrate to the damaged site. We have shown that during stimulation of the myeloid cells adenosine receptors for 72 h an alternative antigenic phenotype developed, which differed from that of (adenosine) unstimulated cells: the expression of the monocyte marker CD14 was preserved with already expressed dendritic cell markers (CD209, CD1a). These cells had also higher levels of mRNA expression of proinflammatory cytokines and chemoattractants (IL-6, IL-8, IL-1β). Being injected into the site of the burn injury the adenosine modified myeloid cells increased the bulk density of the mixed cellular infiltrate (granulocytes, monocytes, fibroblasts) by day 7. Thus, we have found that one of the effects of adenosine at the site of burn injury consists in increased migration of granulocytes and monocytes in response to the increased production of paracrine factors by myeloid cells.

Keywords

adenosine monocyte burn injury paracrine factor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gorlach, A., Circ. Res., 2005, vol. 97, pp. 1–3.CrossRefGoogle Scholar
  2. 2.
    Hasko, G. and Cronstein, B., Trends in Immunology, 2004, vol. 25, no. 1, pp. 33–39.CrossRefGoogle Scholar
  3. 3.
    Hasko, G. and Pacher, P., J. Leukoc. Biol., 2008, vol. 3, pp. 447–455.Google Scholar
  4. 4.
    Feoktistov, I., Goldstein, A.E., Ryzhov, S., Zeng, D., Belardinelli, L., Voyno-Yasenetskaya, T., and Biaggioni, I., Circ. Res., 2002, vol. 90, pp. 531–538.CrossRefGoogle Scholar
  5. 5.
    Palmer, T.M. and Stiles, G.L., Neuropharmacology, 1995, vol. 34, pp. 683–694.CrossRefGoogle Scholar
  6. 6.
    Young, H.W., Molina, J.G., Dimina, D., Zhong, H., Jacobson, M., Chan, L.N., Chan, T.S., Lee, J.J., and Blackburn, M.R., J. Immunol., 2004, vol. 173, pp. 1380–1389.CrossRefGoogle Scholar
  7. 7.
    Zhao, Z., Yaar, R., Ladd, D., Cataldo, L.M., and Ravid, K., Microvasc. Res., 2002, vol. 63, pp. 61–69.CrossRefGoogle Scholar
  8. 8.
    Haskó, G., Linden, J., Cronstein, B., and Pacher, P., Nat. Rev. Drug Discov., 2008, vol. 7, no. 9, pp. 759–770.CrossRefGoogle Scholar
  9. 9.
    Reece, T.B., Ellman, P.E, Maxey, T.S., Crosby, I.K., Warren, P.S., Chong, T.W., LeGallo, R.D., Linden, J., Kern, J.A., Tribble, C.G., and Kron, I.L., J. Thorac. Cardiovasc. Surg., 2005, vol. 129, pp. 1137–1143.CrossRefGoogle Scholar
  10. 10.
    Luijk, B., van den Berge, M., Kerstjens, H.A., Postma, D.S., Cass, L., Sabin, A., and Lammers, J.W., Allergy, 2008, vol. 63, pp. 75–80.Google Scholar
  11. 11.
    Schwacha, M., Nickel, E., and Daniel, T., Mol. Med., 2008, vol. 14, nos. 9–10, pp. 628–633.Google Scholar
  12. 12.
    Fredholm, B.B., Cell Death Differ, 2007, vol. 14, no. 7, pp. 1315–1323.CrossRefGoogle Scholar
  13. 13.
    Shaked, G., Gurfinkel, R., Czeiger, D., Douvdevani, A., and Sufaro, Y., Burns, 2007, vol. 33, no. 3, pp. 352–354.CrossRefGoogle Scholar
  14. 14.
    Shulte, G., Adenosine Receptor Signaling and the Activation of Mitogen-Activated Protein Kinases, Stockholm: Repo Print, 2002.Google Scholar
  15. 15.
    Cronstein, B.N., F1000 Biol. Rep., 2011, vol. 3, pp. 21–27.CrossRefGoogle Scholar
  16. 16.
    Cronstein, B.N., J. Appl. Physiol., 1994, vol. 76, pp. 5–13.Google Scholar
  17. 17.
    Ham, J. and Rees, D.A., Endocr. Metab. Immune Disord. Drug Targets, 2008, vol. 8, pp. 244–254.CrossRefGoogle Scholar
  18. 18.
    Palmer, T.M. and Trevethick, M.A., Br. J. Pharmacol., 2008, vol. 153, pp. 27–34.CrossRefGoogle Scholar
  19. 19.
    Kreckler, L.M., Gizewski, E., Wan, T.C., and Auchampach, J.A., J. Pharmacol. Exp. Ther., 2009, vol. 331, no. 3, pp. 1051–1061.CrossRefGoogle Scholar
  20. 20.
    Ryzhov, S., Novitskiy, S.V., Goldstein, A.E., Biktasova, A., Blackburn, M.R., Biaggioni, I., Dikov, M.M., and Feoktistov, I., J. Immunol., 2011, vol. 187, no. 11, pp. 6120–6129.CrossRefGoogle Scholar
  21. 21.
    Wilson, J.M., Kurtz, C.C., Black, S.G., Ross, W.G., Alam, M.S., Linden, J., and Ernst, P.B., J. Immunol., 2011, vol. 186, no. 12, pp. 6746–6752.CrossRefGoogle Scholar
  22. 22.
    Ryzhov, S., Zaynagetdinov, R., Goldstein, A.E., Novitskiy, S.V., Blackburn, M.R., Biaggioni, I., and Feoktistov, I., J. Pharmacol. Exp. Ther., 2008, vol. 324, no. 2, pp. 694–700.CrossRefGoogle Scholar
  23. 23.
    Novitskiy, S.V., Ryzhov, S., Zaynagetdinov, R., Goldstein, A.E., Huang, Y., Tikhomirov, O.Y., Blackburn, M.R., Biaggioni, I., Carbone, D.P., Feoktistov, I., and Dikov, M.M., Blood, 2008, vol. 112, no. 5, pp. 1822–1831.CrossRefGoogle Scholar
  24. 24.
    Clahsen, T., and Schaper, F., J. Leukoc. Biol., 2008, vol. 84, no. 6, pp. 1521–1529.CrossRefGoogle Scholar
  25. 25.
    Varyushina, E.A., Rozlomii, V.L., Aleksandrov, G.V., Rybal’chenko, O.V., Potokin, I.L., Isaeva, E.N., and Simbirtsev, A.S., Tsitokiny i Vospalenie, 2010, vol. 2, pp. 7–12.Google Scholar

Copyright information

© Pleiades Publishing, Ltd. 2014

Authors and Affiliations

  • K. S. Yuryeva
    • 1
  • K. V. Nevskaya
    • 1
  • A. N. Dzuman
    • 1
  • O. P. Ikkert
    • 1
  • V. V. Ivanov
    • 1
  • I. V. Saltikova
    • 1
  • A. E. Sazonov
    • 1
  • L. M. Ogorodova
    • 1
  1. 1.Siberian State Medical UniversityTomskRussia

Personalised recommendations